Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 3Phase 1/2 2

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1CNS 1

Conditions

Pancreatic Neoplasms 1Pain 1Neurofibromatosis 1 1Neurofibroma, Plexiform 1

Interventions

pembrolizumab 35Carboplatin 24Specimen Handling 20Cyclophosphamide 18Magnetic Resonance Spectroscopy 17fludarabine 15Nivolumab 14Dexamethasone 14Bevacizumab 14Gemcitabine 12Biopsy 12atezolizumab 11Temozolomide 11Paclitaxel 10venetoclax 9Pemetrexed 9Ipilimumab 9Docetaxel 9Cisplatin 9Rituximab 8Lenalidomide 8blinatumomab 7Prednisone 7Oxaliplatin 7Fluorouracil 7Capecitabine 7olaparib 6lenvatinib 6Vincristine 6Radiotherapy 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × AZD 6244 × 30 days × Clear all
NCT07619521 2026-06-02

Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a, for Advanced Pancreatic Ductal Adenocarcinoma

National Cancer Institute (NCI)

Phase 1/2 Not yet recruiting
31 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT01362803 2026-06-01

AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors

National Institutes of Health Clinical Center (CC)

Phase 1/2 Active not recruiting
99 enrolled 1 FDA
CNS

Neurofibromatosis 1, Pain, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon âš¡